Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 5 September 2003:
Vol. 301. no. 5638, pp. 1371 - 1374
DOI: 10.1126/science.1088902
Prev | Table of Contents | Next

Reports

Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1

Yili Yin,1 Bénédicte Manoury,2 Robin Fåhraeus1*

The glycine-alanine repeat domain (GAr) of Epstein-Barr virus–encoded nuclear antigen 1 (EBNA1) prevents major histocompatibility complex (MHC) class I–restricted presentation of EBNA1 epitopes to cytotoxic T cells. This effect has previously been attributed to the ability of GAr to inhibit its own proteasomal degradation. Here we show, both in vitro and in vivo, that GAr also inhibits messenger RNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Hence, inhibition of messenger RNA translation, but not protein degradation, is essential to prevent antigen presentation on MHC class I molecules. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid cytotoxic T cell recognition. At the same time, blocking degradation maintains the EBNA1 expression level.

1 Division of Molecular Physiology, Faculty of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
2 Division of Cell Biology and Immunology, Faculty of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.

* To whom correspondence should be addressed. E-mail: r.fahraeus{at}dundee.ac.uk

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
mRNA Translation Regulation by the Gly-Ala Repeat of Epstein-Barr Virus Nuclear Antigen 1.
S. Apcher, A. Komarova, C. Daskalogianni, Y. Yin, L. Malbert-Colas, and R. Fahraeus (2009)
J. Virol. 83, 1289-1298
   Abstract »    Full Text »    PDF »
In vivo imaging of murid herpesvirus-4 infection.
R. Milho, C. M. Smith, S. Marques, M. Alenquer, J. S. May, L. Gillet, M. Gaspar, S. Efstathiou, J. P. Simas, and P. G. Stevenson (2009)
J. Gen. Virol. 90, 21-32
   Abstract »    Full Text »    PDF »
Reduction in RNA Levels Rather than Retardation of Translation Is Responsible for the Inhibition of Major Histocompatibility Complex Class I Antigen Presentation by the Glutamic Acid-Rich Repeat of Herpesvirus Saimiri Open Reading Frame 73.
J. Gao, J. M. Coulson, A. Whitehouse, and N. Blake (2009)
J. Virol. 83, 273-282
   Abstract »    Full Text »    PDF »
Gly-Ala Repeats Induce Position- and Substrate-specific Regulation of 26 S Proteasome-dependent Partial Processing.
C. Daskalogianni, S. Apcher, M. M. Candeias, N. Naski, F. Calvo, and R. Fahraeus (2008)
J. Biol. Chem. 283, 30090-30100
   Abstract »    Full Text »    PDF »
A Mobile Functional Region of Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein Independently Regulates DNA Binding and Protein Abundance.
P.-J. Chang, D. Shedd, and G. Miller (2008)
J. Virol. 82, 9700-9716
   Abstract »    Full Text »    PDF »
From the Cover: Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition.
J. Tellam, C. Smith, M. Rist, N. Webb, L. Cooper, T. Vuocolo, G. Connolly, D. C. Tscharke, M. P. Devoy, and R. Khanna (2008)
PNAS 105, 9319-9324
   Abstract »    Full Text »    PDF »
Immune surveillance obstructed by viral mRNA.
S. R. Starck, S. Cardinaud, and N. Shastri (2008)
PNAS 105, 9135-9136
   Full Text »    PDF »
Autorepression of Epstein-Barr Virus Nuclear Antigen 1 Expression by Inhibition of Pre-mRNA Processing.
M. Yoshioka, M. M. Crum, and J. T. Sample (2008)
J. Virol. 82, 1679-1687
   Abstract »    Full Text »    PDF »
Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Mimics Epstein-Barr Virus EBNA1 Immune Evasion through Central Repeat Domain Effects on Protein Processing.
H. J. Kwun, S. R. da Silva, I. M. Shah, N. Blake, P. S. Moore, and Y. Chang (2007)
J. Virol. 81, 8225-8235
   Abstract »    Full Text »    PDF »
Epstein-Barr Virus Transcription Activator Rta Upregulates Decoy Receptor 3 Expression by Binding to Its Promoter.
C.-H. Ho, C.-F. Hsu, P.-F. Fong, S.-K. Tai, S.-L. Hsieh, and C.-J. Chen (2007)
J. Virol. 81, 4837-4847
   Abstract »    Full Text »    PDF »
Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes.
J. Tellam, M. H. Fogg, M. Rist, G. Connolly, D. Tscharke, N. Webb, L. Heslop, F. Wang, and R. Khanna (2007)
J. Exp. Med. 204, 525-532
   Abstract »    Full Text »    PDF »
Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
Y. Ito, A. Demachi-Okamura, R. Ohta, Y. Akatsuka, K. Nishida, K. Tsujimura, Y. Morishima, T. Takahashi, and K. Kuzushima (2007)
J. Gen. Virol. 88, 770-780
   Abstract »    Full Text »    PDF »
Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells.
D. Lagos, M. W. B. Trotter, R. J. Vart, H.-W. Wang, N. C. Matthews, A. Hansen, O. Flore, F. Gotch, and C. Boshoff (2007)
Blood 109, 1550-1558
   Abstract »    Full Text »    PDF »
Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope.
C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J. F. Seymour, M. Gandhi, et al. (2006)
J. Immunol. 177, 4897-4906
   Abstract »    Full Text »    PDF »
Viral strategies for evading antiviral cellular immune responses of the host.
A. Iannello, O. Debbeche, E. Martin, L. H. Attalah, S. Samarani, and A. Ahmad (2006)
J. Leukoc. Biol. 79, 16-35
   Abstract »    Full Text »    PDF »
Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma.
K. C. Straathof, A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard (2005)
J. Immunol. 175, 4137-4147
   Abstract »    Full Text »    PDF »
Reconstitution of EBV Latent but Not Lytic Antigen-Specific CD4+ and CD8+ T Cells after HIV Treatment with Highly Active Antiretroviral Therapy.
E. Piriou, C. A. Jansen, K. v. Dort, I. De Cuyper, N. M. Nanlohy, J. M. A. Lange, M. H. J. van Oers, F. Miedema, and D. van Baarle (2005)
J. Immunol. 175, 2010-2017
   Abstract »    Full Text »    PDF »
Transcription of the murine gammaherpesvirus 68 ORF73 from promoters in the viral terminal repeats.
H. M. Coleman, S. Efstathiou, and P. G. Stevenson (2005)
J. Gen. Virol. 86, 561-574
   Abstract »    Full Text »    PDF »
Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy.
C. Paludan, D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Munz (2005)
Science 307, 593-596
   Abstract »    Full Text »    PDF »
Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion.
M. E. Ressing, D. van Leeuwen, F. A. W. Verreck, S. Keating, R. Gomez, K. L. M. C. Franken, T. H. M. Ottenhoff, M. Spriggs, T. N. Schumacher, L. M. Hutt-Fletcher, et al. (2005)
J. Virol. 79, 841-852
   Abstract »    Full Text »    PDF »
Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy.
S. R. Riddell (2004)
J. Exp. Med. 200, 1533-1537
   Abstract »    Full Text »    PDF »
Epstein-Barr Virus Nuclear Antigen 1: from Immunologically Invisible to a Promising T Cell Target.
C. Munz (2004)
J. Exp. Med. 199, 1301-1304
   Abstract »    Full Text »    PDF »
CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1.
S. P. Lee, J. M. Brooks, H. Al-Jarrah, W. A. Thomas, T. A. Haigh, G. S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J. L. Yates, et al. (2004)
J. Exp. Med. 199, 1409-1420
   Abstract »    Full Text »    PDF »
Endogenous Presentation of CD8+ T Cell Epitopes from Epstein-Barr Virus-encoded Nuclear Antigen 1.
J. Tellam, G. Connolly, K. J. Green, J. J. Miles, D. J. Moss, S. R. Burrows, and R. Khanna (2004)
J. Exp. Med. 199, 1421-1431
   Abstract »    Full Text »    PDF »
Kaposi's Sarcoma-Associated Herpesvirus K7 Protein Targets a Ubiquitin-Like/Ubiquitin-Associated Domain-Containing Protein To Promote Protein Degradation.
P. Feng, C. W. Scott, N.-H. Cho, H. Nakamura, Y.-H. Chung, M. J. Monteiro, and J. U. Jung (2004)
Mol. Cell. Biol. 24, 3938-3948
   Abstract »    Full Text »    PDF »
Repeat Sequence of Epstein-Barr Virus-encoded Nuclear Antigen 1 Protein Interrupts Proteasome Substrate Processing.
M. Zhang and P. Coffino (2004)
J. Biol. Chem. 279, 8635-8641
   Abstract »    Full Text »    PDF »
Dendritic cell aggresome-like induced structures are dedicated areas for ubiquitination and storage of newly synthesized defective proteins.
H. Lelouard, V. Ferrand, D. Marguet, J. Bania, V. Camosseto, A. David, E. Gatti, and P. Pierre (2004)
J. Cell Biol. 164, 667-675
   Abstract »    Full Text »    PDF »
Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes.
K. S. Voo, T. Fu, H. Y. Wang, J. Tellam, H. E. Heslop, M. K. Brenner, C. M. Rooney, and R.-F. Wang (2004)
J. Exp. Med. 199, 459-470
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)